NYSE:LLY 12 December 2025 - 23 December 2025

Eli Lilly and Company enters the final full holiday trading week of 2025 with momentum—and with headlines that can move the stock quickly in thin year‑end liquidity. The most important story remains Lilly’s dominance in obesity and diabetes medicines, but investors are now pricing in what comes next: oral GLP‑1 candidates, next‑generation “triple agonist” retatrutide, and a shifting U.S. policy backdrop that’s pushing drugmakers toward direct-to-consumer pricing and discount channels.

As of Sunday, December 21, 2025, Eli Lilly and Company heads into a holiday-shortened trading week near recent highs, after a busy stretch of headlines spanning next-generation obesity drugs, potentially accelerated FDA review timelines, price cuts aimed at widening access, and a fast-evolving U.S. drug-pricing agenda.

December 18, 2025 — Eli Lilly and Company is back in the spotlight after the drugmaker released new Phase 3 results for its experimental oral obesity medicine orforglipron, a development investors have been watching closely as the weight-loss market pushes beyond injections and into pills. At the same time, a report said Lilly is preparing material price cuts in Canada for its blockbuster medicines Mounjaro and Zepbound—a reminder that pricing and access remain central to the long-term investment case. Reuters+2Reuters+2

Dec. 17, 2025 — Eli Lilly and Company finished Wednesday lower and then held steady in extended trading, as investors balanced a risk-off day for equities with fresh headlines on U.S. drug-pricing negotiations, ongoing “rotation” trades favoring healthcare, and new collaboration news tied to next-generation obesity therapeutics.

Eli Lilly and Company stock remains one of the market’s most closely watched healthcare names as 2025 winds down—powered by blockbuster demand for obesity and diabetes medicines, and increasingly driven by what comes next: faster, deeper weight loss therapies, an oral GLP-1 pipeline, and a manufacturing expansion designed to keep up with demand.

December 15, 2025 — Eli Lilly and Company stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the FDA review timeline for oral GLP‑1 candidate orforglipron, ongoing capacity expansion in the U.S., and a notable analyst price-target tweak hitting the tape today. MarketBeat+3Reuters+3Reuters+3

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting.